The IL-6 level in HCC patients is closely linked to tumor progression and relapse, since IL-6 could induce myeloid-derived suppressor cells to inhibit T-cell immunity and enhance HCC progression [27,28,29]. The gene discussed is IL6; the disease is hepatocellular carcinoma.